HCHailey Connolly

Hailey Connolly

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hailey Connolly has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Provider Perspectives on the Role of Hypotension in Pediatric Kidney Transplant: A Pediatric Nephrology Research Consortium Study

    by Hailey Connolly, Olga Charnaya, Sruthi Tatavarthi, Shireen Hashmat

    Background: The lack of a consistent definition for hypotension in the pediatric population complicates the study of hypotension in pediatric kidney transplant recipients. Additionally, there is limited data to guide the management of hypotension in these patients both before and after transplantation. Methods: A 10‐question survey was distributed to pediatric nephrologists. The survey data was analyzed using descriptive statistical methods without hypothesis testing. Results: A total of 25 respondents completed the survey, revealing significant variability in the definitions of hypotension used and in the management approaches for hypotension during the pre‐ and posttransplant periods. Conclusions: There is significant variability in practice patterns regarding the management of hypotension in pediatric transplant recipients. This highlights the need for further research to evaluate the prevalence of chronic hypotension in the pediatric ESKD population and to assess its impact on transplant outcomes.

  • Daratumumab for Treatment of Acute Antibody‐Mediated Rejection in a Pediatric Kidney Transplant Recipient

    by Hailey Connolly, Ally Watson, Michael Wynd, Kenneth Lieberman, Melissa Chaung, Michael J. Goldstein, Guillermo Hidalgo, Ibrahim Batal, Marlene Amoruso, Namrata G. Jain

    Background: Daratumumab, an anti‐CD38 monoclonal antibody, has shown efficacy as a potential treatment for antibody‐mediated rejection (ABMR) following kidney transplantation in adults. Methods: We present a case demonstrating the use of daratumumab for the management of ABMR in a pediatric kidney transplant recipient. Results: The patient underwent a living‐unrelated donor renal transplant with a post‐transplant course complicated by active ABMR. The patient received a total of four daratumumab infusions with a subsequent decrease in serum creatinine, serum donor‐specific antibody levels, and donor‐derived cell‐free DNA (dd‐cfDNA), which remained low 1 year following treatment. Conclusions: Daratumumab may be a promising treatment consideration for the management of ABMR in pediatric patients following renal transplantation, though further research is needed to better understand its efficacy and side effects. DD‐cfDNA may also be a promising tool to monitor treatment response in conjunction with more traditional methods.


  • Open Access

    Probiotic use in pediatric kidney transplant recipients: What are current practices, and are they evidence‐based? A pediatric nephrology research consortium study

    by S. J. Kizilbash, H. Connolly, S. Bartosh, R. Zahr, S. Al‐Akash, A. Chishti, A. Mansuri, H. Tawadrous, N. G. Jain

    Background: Probiotics are living microorganisms that may confer health benefits to their host if administered in sufficient quantities. However, data on the use of probiotics in transplant recipients are scarce.Method: This multi‐center survey of pediatric nephrologists aimed to examine variations in practice regarding the use of probiotics in pediatric kidney transplant recipients. The survey was conducted via a 10‐item questionnaire (developed in Survey Monkey) administered to pediatric nephrologists participating in the Pediatric Nephrology Research Consortium meeting in April 2023.Results: Sixty‐four pediatric nephrologists completed the survey. Twenty‐seven (42.2%) respondents reported having prescribed probiotics to pediatric kidney transplant recipients. The primary reason for probiotic use was the treatment of antibiotic‐associated diarrhea (n = 20), with other reasons including recurrent Clostridium difficile infection (n = 15), general gut health promotion (n = 12), recurrent urinary tract infections (n = 8), and parental request (n = 1). Of those who prescribed probiotics, 48.1% held them during periods of neutropenia and 14.8% during central venous line use. Of the 64 respondents, 20 reported the lack of safety data as a concern for using probiotics in kidney transplant recipients.Conclusion: Pediatric nephrologists are increasingly prescribing probiotics to pediatric kidney transplant recipients; nevertheless, substantial practice variations exist. The paucity of safety data is a significant deterrent to probiotic use in this population.